证券代码：688410 证券简称：山外山 公告编号：2023-057 重庆山外山血液净化技术股份有限公司 关于 2023 年半年度利润分配及资本公积金 转增股本预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配及资本公积金转增股本预案内容 经天职国际会计师事务所（特殊普通合伙）审计，截至 2023 年 6 月 30 日， 公司 2023 年半年度实现归属于上市公司股东的净利润为人民币 134,240,442.45 元，母公司资本公积金余额 1,340,355,286.00 元，母公司期末可供分配利润为 人民币 241,692,951.32 元；经公司第三届董事会第三次会议决议，公司 2023 年半年度拟以实施权益分派股权登记日登记的总股本为基数进行利润分配及资 本公积金转增股本。 ● 每股分配及转增比例：公司拟向全体股东每 10 股派发现金红利人民币 2.00 元（含税），同时以资本公积金向全体股东每 10 股转增 4.9 股。 ● 本次利润分配及资本公积金转增股本以实施权益分派股权登 ...

Financial Performance - The company's operating revenue for Q1 2023 reached ¥193,032,111.71, representing a year-on-year increase of 187.14%[5] - Net profit attributable to shareholders was ¥74,586,123.06, a significant increase of 866.83% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥71,078,708.92, reflecting a year-on-year growth of 1,103.68%[5] - Basic and diluted earnings per share were both ¥0.5153, an increase of 624.75% year-on-year[6] - The total operating revenue for Q1 2023 was CNY 193,032,111.71, a significant increase from CNY 67,225,376.61 in Q1 2022, representing a growth of approximately 187.5%[23] - The net profit for Q1 2023 reached CNY 74,198,500.21, a substantial rise from CNY 7,312,622.81 in Q1 2022, reflecting an increase of approximately 907.5%[25] - The total comprehensive income attributable to the parent company for Q1 2023 was ¥74,586,123.06, compared to ¥7,714,539.65 in Q1 2022, representing a significant increase[26] - Basic and diluted earnings per share for Q1 2023 were both ¥0.5153, up from ¥0.0711 in Q1 2022, indicating a substantial improvement in profitability[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,030,520,823.98, an increase of 5.56% from the end of the previous year[6] - As of March 31, 2023, the company's total current assets amounted to RMB 1,862,705,981.47, an increase from RMB 1,756,545,255.66 as of December 31, 2022, representing a growth of approximately 6.05%[18] - The company's total assets as of Q1 2023 amounted to CNY 2,030,520,823.98, up from CNY 1,923,657,055.17 in the previous year, marking an increase of about 5.6%[20] - The total liabilities for Q1 2023 were CNY 440,880,924.65, compared to CNY 408,641,670.42 in Q1 2022, which is an increase of approximately 7.9%[20] Cash Flow - The net cash flow from operating activities was ¥49,621,308.92, reflecting a significant increase in cash received from sales compared to the same period last year[10] - Net cash flow from operating activities for Q1 2023 was ¥49,621,308.92, a turnaround from a negative cash flow of ¥6,188,908.59 in Q1 2022[28] - Cash inflow from operating activities totaled ¥252,235,785.99 in Q1 2023, compared to ¥75,744,422.97 in the same period last year, reflecting a growth of 233%[28] - Cash outflow for operating activities was ¥202,614,477.07 in Q1 2023, compared to ¥81,933,331.56 in Q1 2022, showing an increase of 147%[28] - The company reported a net increase in cash and cash equivalents of ¥20,292,229.89 for Q1 2023, contrasting with a decrease of ¥16,713,855.22 in Q1 2022[28] - The ending balance of cash and cash equivalents as of the end of Q1 2023 was ¥1,488,164,956.19, compared to ¥154,809,279.39 at the end of Q1 2022[28] Research and Development - Research and development expenses totaled ¥6,061,357.91, accounting for 3.14% of operating revenue, down from 5.55%[6] - The company's R&D expenses in Q1 2023 were CNY 5,933,038.80, up from CNY 3,983,811.33 in Q1 2022, indicating a growth of about 48.9%[23] Shareholder Information - The company reported a total of 7,334 common shareholders at the end of the reporting period[12] - The company has identified several key shareholders, with the largest holding being China Industrial Bank Co., Ltd. with 1,384,146 shares[14] Subsidiary Transfers - The company decided to transfer its subsidiary, Chongqing Shanchuan Blood Dialysis Center Co., Ltd., for RMB 4 million due to high operational costs[15] - Another subsidiary, Junlian Kanda Blood Dialysis Center Co., Ltd., was also transferred for RMB 2.5 million, again due to ongoing losses[15] Inventory and Receivables - The company's inventory increased to RMB 180,093,298.00 from RMB 133,686,275.33, marking a rise of about 34.8%[18] - The company reported an increase in accounts receivable to RMB 117,121,708.93 from RMB 116,035,138.39, a slight increase of about 0.93%[18] - The prepayments rose to RMB 22,786,725.80 from RMB 9,787,626.87, showing an increase of approximately 132.5%[18] Financial Activities - The company has not reported any significant changes in its financing and securities business activities during the reporting period[14] - The company is not applying new accounting standards or interpretations for the first time in 2023, ensuring consistency in financial reporting[29]

证券代码：688410 证券简称：山外山 公告编号：2023-024 重庆山外山血液净化技术股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 重庆山外山血液净化技术股份有限公司（以下简称"公司"）已于 2023 年 04 月 03 日发布公司 2022 年年度报告，同时于 2023 年 3 月 30 日召开了公司第 二届董事会第十九次会议和第二届监事会第十二次会议审议通过了《关于 2022 年度利润分配预案的议案》，不进行利润分配，不派发现金股利，不送红股， 不以资本公积金转增股本。相关公告详见公司于 2023 年 4 月 3 日在上海证券交 易所网站（www.sse.com.cn）披露的相关公告。 为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况及 现金分红等具体情况，公司计划于 2023 年 04 月 17 日（星期一）下午 15:00- 16:30 举行 2022 年度业绩暨现金分红说明会，就投资者关心的问题进行交流。 ...

Financial Performance - The company reported no profit distribution for the 2022 fiscal year, with no cash dividends or stock bonuses planned, due to significant funding needs for industry development and expansion of R&D projects [7]. - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15% [13]. - The company expects a revenue growth of 10% for the upcoming fiscal year, projecting total revenue to reach RMB 1.32 billion [15]. - The company achieved a net profit of RMB 300 million, reflecting a profit margin of 25% for the year 2022 [15]. - The company achieved operating revenue of CNY 382,012,680.92 in 2022, representing a year-on-year increase of 34.85% [22]. - Net profit attributable to shareholders reached CNY 59,237,048.20, a significant increase of 204.20% compared to the previous year [22]. - The net cash flow from operating activities surged to CNY 245,850,595.84, marking a 650.41% increase year-on-year [22]. - The gross margin for the year was reported at 45%, a slight increase from 42% in the previous year [15]. - The company’s net profit for 2022 increased by 213.68%, driven by a net profit increase of 23.1 million CNY in the blood purification equipment segment and 7.44 million CNY in the medical services segment [154]. Research and Development - The company is investing RMB 100 million in research and development for innovative blood purification technologies over the next two years [14]. - Research and development expenses accounted for 6.98% of operating revenue, a decrease of 2.92 percentage points from the previous year [24]. - The company registered 4 new products, including dialysis fluid filters and blood dialysis devices, enhancing its product portfolio [37]. - The company has obtained 12 patent authorizations during the reporting period, bringing the total to 130 patents [38]. - The company has a multidisciplinary R&D team that has developed key technologies for blood purification products, resulting in the launch of five major product series [124]. - The company has applied for a total of 32 patents during the reporting period and obtained 19 patents, bringing the cumulative total to 38 invention patents [105]. - The company is focused on R&D investment and new product development, particularly in smart blood purification devices and related technologies [100]. Market Expansion and Strategy - The company plans to expand its market presence by entering three new provinces in China by the end of 2023, targeting an additional 50,000 patients [15]. - A strategic acquisition of a local medical device company was completed, which is anticipated to increase the company's market share by 5% [13]. - The company is expanding its international business by participating in global medical exhibitions and leveraging favorable policies like the Belt and Road Initiative to explore new markets [46]. - The company aims to improve the convenience of its products, which may lead to increased adoption in clinical settings [115]. - The company is committed to expanding its market presence through technological advancements and strategic partnerships in the healthcare sector [87][88]. Governance and Compliance - The audit report issued by Tianzhi International Accounting Firm confirmed the financial statements' accuracy and completeness [5]. - The board of directors and supervisory board members have all attended the board meeting, ensuring governance compliance [5]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties [9]. - There are no violations of decision-making procedures regarding external guarantees [9]. - The company has not experienced any inability of the majority of directors to ensure the authenticity and completeness of the annual report [9]. Risks and Challenges - The company has outlined potential risks related to future plans and strategies, emphasizing the need for investors to be cautious [8]. - The company faces risks related to new product development, including long R&D cycles and high investment costs, which could lead to potential failures [128]. - The company is at risk of losing core technical personnel, which is critical for maintaining its technological advantage in a competitive market [130]. - The company is exposed to risks from competitive pressures in the blood purification equipment and consumables market, particularly from established foreign brands [146]. - The company is at risk of reduced patient numbers and revenue due to potential changes in national medical insurance policies affecting reimbursement rates and coverage [145]. Product Development and Innovation - New product development includes the launch of a next-generation hemodialysis machine, which is expected to enhance treatment efficiency by 30% [14]. - The company has developed a comprehensive blood purification ecosystem, integrating equipment, consumables, medical services, and information management systems [72]. - The company has developed key technologies for continuous renal replacement therapy (CRRT), dialysis machines, and blood perfusion machines, with products widely used for various kidney-related conditions [199]. - The company has developed a new type of dialysis device structure that enhances blood and dialysis fluid contact, improving the clearance capacity of the dialysis membrane and effectively avoiding coagulation and hemolysis phenomena [98]. - The company has developed a blood purification system that monitors physiological parameters such as blood pressure, blood volume, and temperature, ensuring patient safety and treatment efficacy [89]. Supply Chain and Procurement - The procurement model includes a strict supplier evaluation system to ensure the quality and stability of raw materials, with a focus on key materials [58]. - The procurement process involves a minimum of three qualified suppliers for medical consumables, ensuring competitive pricing and quality [62]. - The company has established a robust supply chain for raw materials, ensuring timely supply and reducing procurement risks [59]. - The company’s total procurement from the top five suppliers was 56,283,081.26 RMB, with no significant reliance on any single supplier [171]. Customer Engagement and Service - The company maintains a comprehensive after-sales service system, committing to reach user sites within 48 hours of service requests [69]. - The company has developed a patient management system for dialysis centers, improving patient case management and inventory management [116]. - The company guarantees a 48-hour response time for after-sales service, ensuring customer satisfaction and loyalty through regular maintenance and training [126]. Industry Trends and Market Insights - The global dialysis market size increased from €66.8 billion in 2015 to €82 billion in 2020, with an annual growth rate of approximately 4%, and is projected to reach nearly €100 billion by 2025 [70]. - In China, the number of patients receiving dialysis treatment grew from 234,600 in 2011 to 749,600 in 2021, with a compound annual growth rate of 12.3% over the decade [76]. - The domestic blood purification market is expected to grow rapidly due to increasing kidney disease patient numbers and higher reimbursement rates for dialysis treatment [71]. - The company is positioned to accelerate domestic substitution in the blood dialysis industry due to strong governmental policy support and market demand [80].